Shukaib Arslan is an Oncology physician. OpenAlex indexes 147 publications with 831 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6202 Harry Hines Blvd
Dallas, TX 753900001
Telephone
214-645-4673Provider last certified this registry record 5 Feb 2026.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year20242 payments
- National Marrow Donor ProgramProgram year20241 payment
- AstraZeneca UK LimitedProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
29.2%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor29.2%Acyclovir100%Part D≥14 patientsAnti-infectives
26.8%Fluoroquinolone Antibacterial12.4%Levofloxacin100%Part D<11 patientsAzole Antifungal9.1%Posaconazole100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
20.1%Kinase inhibitor7.7%Jakafi100%Part D<11 patientsIsocitrate Dehydrogenase 2 Inhibitor6.7%Idhifa100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease
Expert Opinion on Investigational Drugs
2025 - Current status and future potential of CD123-based targeted therapies for acute leukemia
Expert Opinion on Biological Therapy
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”